News & Events

Publications

Advances in Therapy publishes Pharma Two B’s review paper, “P2B001 (extended release pramipexole and rasagiline): A new treatment option in development for Parkinson’s disease”

March 14, 2022

Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren & Pninit Litman Published: 10 March 2022 Advances in TherapyDOI: 10.1007/s12325-022-02097-2 Abstract

A Randomized Trial of a Low Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease

April 3, 2017

C. Warren Olanow MD, Karl Kieburtz MD, Mika Leinonen MSc, Lawrence Elmer MD, Nir Giladi MD, Robert A. Hauser MD, Olga S. Klepiskaya MD, David

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease

June 30, 2015

Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the

Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval

April 22, 2011

Published in Scrip Magazine by Donna Young, April 22nd 2011 Israeli start-up Pharma Two B has taken the concept of synergism seriously, from the eclectic